Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Cipla Limited (BSE: 5
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
Pfizer and BioNTech on Monday submitted preliminary clinical data to US health authorities as part of their effort to seek authorization for a third dose of their Covid-19 vaccine for all Americans.
Last week, the United States approved the booster shot of Pfizer-BioNTech and Moderna vaccines for people with weakened immune systems.
“The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels that significantly exceed those seen after the two-dose primary schedule,” Albert Bourla, Pfizer’s Chairman and Chief Executive Officer, said in a statement.
“A booster vaccine could help reduce infection and disease rates in people who have previously been vaccinated and better control the spread of virus variants during the coming season,” said BioNTech Co-founder Ugur Sahin.
The companies plan to submit the same information to European authorities in the coming weeks.
The move comes despite appeals by the World Health Organization for a moratorium on booster shots to help ease the drastic inequity in dose distribution between rich and poor nations. Israel has also began administering third doses to its citizens.
